JP Morgan Maintains GoodRx Holdings Inc - (GDRX) Neutral Recommendation

Fintel reports that on September 14, 2023, JP Morgan maintained coverage of GoodRx Holdings Inc - (NASDAQ:GDRX) with a Neutral recommendation.

Analyst Price Forecast Suggests 36.69% Upside

As of August 31, 2023, the average one-year price target for GoodRx Holdings Inc - is 8.56. The forecasts range from a low of 6.06 to a high of $12.60. The average price target represents an increase of 36.69% from its latest reported closing price of 6.26.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for GoodRx Holdings Inc - is 799MM, an increase of 7.23%. The projected annual non-GAAP EPS is 0.27.

What is the Fund Sentiment?

There are 225 funds or institutions reporting positions in GoodRx Holdings Inc -. This is a decrease of 5 owner(s) or 2.17% in the last quarter. Average portfolio weight of all funds dedicated to GDRX is 0.23%, a decrease of 2.18%. Total shares owned by institutions decreased in the last three months by 1.15% to 135,138K shares. The put/call ratio of GDRX is 0.30, indicating a bullish outlook.

What are Other Shareholders Doing?

Francisco Partners Management holds 84,701K shares representing 21.29% ownership of the company. No change in the last quarter.

Silver Lake Group, L.L.C. holds 3,532K shares representing 0.89% ownership of the company. No change in the last quarter.

Petrus Trust Company, LTA holds 2,904K shares representing 0.73% ownership of the company. In it's prior filing, the firm reported owning 2,555K shares, representing an increase of 12.03%. The firm decreased its portfolio allocation in GDRX by 6.91% over the last quarter.

Renaissance Technologies holds 2,498K shares representing 0.63% ownership of the company. In it's prior filing, the firm reported owning 2,247K shares, representing an increase of 10.04%. The firm increased its portfolio allocation in GDRX by 6.62% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,333K shares representing 0.59% ownership of the company. No change in the last quarter.

GoodRx Holdings Background Information
(This description is provided by the company.)

GoodRx Holdings, Inc. is a holding company that provides price comparison tool for prescriptions. The Company provides GoodRx platform, which aggregates and analyzes pricing data from a number of different sources. Its platform also provides access to medication savings programs, medical provider consultations and lab tests through its telehealth offerings, HeyDoctor and the GoodRx Telehealth Marketplace, and other healthcare related content. Its prescription offering provides price comparisons and negotiated prices on prescriptions. Its subscription offerings provide consumers and their families with access to lower prescription prices on select medications in select pharmacies for a monthly or annual subscription fee. Its pharmaceutical manufacturer solutions offering provides advertising and integrated consumer affordability solutions to pharmaceutical manufacturers.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.